WHO Position Paper on Meningococcal vaccines
ثبت نشده
چکیده
Neisseria meningitidis, an exclusive pathogen of humans, remains the leading worldwide cause of meningitis and fatal sepsis, usually in otherwise healthy individuals. In recent years, significant advances have improved our understanding of the epidemiology and genetic basis of meningococcal disease and led to progress in the development of the next generation of meningococcal vaccines. This review summarizes current knowledge of the human susceptibility to and the epidemiology and molecular pathogenesis of meningococcal disease.
منابع مشابه
Immunological Aspect of Meningococcal disease: An overview in Host- Bacteria Interaction
Meningococcal disease remains a significant global public health and is unique among causes of bacterial meningitis and sepsis where it not only causes sporadic disease but also outbreaks. Meningococcal disease has a rapid onset with high mortality. The understanding of immunopathogenesis is crucial for development of novel therapeutic strategies and vaccines designed against meningococcal dise...
متن کاملUse of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015
In October 2014, the Food and Drug Administration (FDA) licensed the first serogroup B meningococcal (MenB) vaccine (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.]) as a 3-dose series. In January 2015, FDA licensed a second MenB vaccine (MenB-4C [Bexsero, Novartis Vaccines]) as a 2-dose series. Both vaccines were approved for use in persons aged 10-25 years. Following outbreaks of serogroup ...
متن کاملNeed for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands
Invasive meningococcal disease (IMD) is a severe bacterial infectious disease with high mortality and morbidity rates worldwide. In recent years, industrialised countries have implemented vaccines targeting IMD in their National Immunisation Programmes (NIPs). In 2002, the Netherlands successfully implemented a single dose of meningococcal serogroup C conjugate vaccine at the age of 14 months a...
متن کاملThe acceptance of three simultaneous vaccine injections recommended at 12 months of age.
Since January 2003, vaccination with Meningococcal C conjugate vaccine (MenCCV) is recommended at 12 months of age, at the same time as the measles-mumps-rubella (MMR) and Haemophilus influenzae type b (Hib) vaccines. Most (83%) of a cohort of 751 children in north Queensland born in January 2003 received the three injectable vaccines simultaneously. Of the 122 children who had not received Men...
متن کاملEvaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
Endemic and epidemic meningococcal disease constitutes a major public-health problem in African countries of the 'meningitis belt' where incidence rates of the disease are many-fold higher (up to 25 cases per 100,000 population) than those in industrialized countries, and epidemics of meningococcal disease occur with rates as high as 1,000 cases per 100,000 people. Using the precedent establish...
متن کامل